Compared with the mice treated with mUTD cells, Nectin4 mCAR-T therapy at low dosage had no significant anti-tumor effect, but prolonged survival and even cured two mice without recurrence at high dosage (Figures 4F, G). This evidence concerns the gene NECTIN4 and neoplasm.